

IN THE UNITED STATE PATENT AND TRADEMARK OFFICE

In re the Application of: Garvey et al

Application No: **09/478,222**

Group Art Unit: 1627

Filed: January 5, 2000

For:

Examiner: B. Celsa

9

Attorney Docket No: 102258.346

Commissioner of Patents PO Box 1450 Alexandria, VA 22313-1450

TERMINAL DISCLAIMER

Methods for Treating Human Impotence with Nitric Oxide Donor Compounds

NitroMed, Inc. certifies that it is the owner of the entire right, title and interest in U.S. Application No. 09/478,222, filed January 5, 2000, entitled "Methods for Treating Human Impotence with Nitric Oxide Donor Compounds" (hereafter the "above-identified application")" by virtue of an assignment recorded in the U.S. Patent and Trademark Office on July 13, 1999, at Reel 010241, Frame 0438.

NitroMed, Inc. also certifies that it is the owner of the entire right, title and interest in U.S. Application No. 09/850,081, filed May 8, 2001, entitled "Compositions of S-nitrosothiols and Methods of Treating Sexual Dysfunctions" by virtue of an assignment recorded in the U.S. Patent and Trademark Office on May 8, 2001, at Reel 011786, Frame 0802 and an assignment recorded in the U.S. Patent and Trademark Office on May 23, 2003, at Reel 014098, Frame 0463

Pursuant to 37 C.F.R. § 1.321, NitroMed, Inc. hereby disclaims the terminal part of any patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory term of any patent issuing from U.S. Application No. 09/850,081, and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to any patent issuing from U.S. Application No. 09/850,081, this agreement to run with any

01/14/2004 MBELETE1 00000150 080219 09478222

02 FC:2814 03 FC:2814 55.00 DA 55.00 DA

Terminal Disclaimer U.S. Application No. 09/478,222

patent granted on the above-identified application and to be binding upon the grantor, its successors or assigns.

NitroMed, Inc. does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of any patent issuing from U.S. Application No. 09/850,081, in the event that any patent issuing from U.S. Application No. 09/850,081 later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.32(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to expiration of its statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

By:

Edward D. Grieff

Attorney for Applicants

HALE AND DORR LLP

1455 Pennsylvania Avenue, NW

Washington, DC 20004 Phone: 202-942-8400

Date: January 12, 2004